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Little is known about the causes of meningioma. Obesity and obesity-related traits have been 
reported in several epidemiological observational studies to be risk factors for meningioma. We 
performed an analysis of genetic variants associated with obesity-related traits to assess the 
relationship with meningioma risk using Mendelian randomization (MR), an approach 
unaffected by biases from temporal variability and reverse causation that might have affected 
earlier investigations. We considered 11 obesity-related traits, identified genetic instruments for 
these factors, and assessed their association with meningioma risk using data from a genome-
wide association study comprising 1,606 meningioma patients and 9,823 controls. To evaluate 
the causal relationship between the obesity-related traits and meningioma risk, we consider the 
estimated odds ratio (OR) of meningioma for each genetic instrument. We identified positive 
associations between body mass index (odds ratio [ORSD]=1.27, 95% confidence interval 
[CI]=1.03-1.56, P=0.028) and body fat percentage (ORSD=1.28, 95% CI=1.01-1.63, P=0.042) 
with meningioma risk, albeit non-significant after correction for multiple testing. Associations 
for basal metabolic rate, diastolic blood pressure, fasting glucose, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, systolic blood pressure, total cholesterol, 
triglycerides and waist circumference with risk of meningioma were non-significant. Our 
analysis provides additional support for obesity being associated with an increased risk of 
meningioma.  
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INTRODUCTION 
 
Meningioma is the commonest form of brain tumour, affecting approximately one per cent of the 
adult population 1. Although mortality from meningioma is generally low, the disease is 
associated with substantial morbidity. 
 
Thus far, little is known about the aetiological basis of meningioma with few well-established 
risk factors for the disease 2,3. There is increasing recognition that obesity and obesity-related 
traits, such as body mass index (BMI), are risk factors for common cancers such as breast, colon, 
ovarian, renal and pancreatic 4. Observational epidemiological studies have however provided 
inconsistent evidence for obesity and obesity-related traits being risk factors for meningioma 5-12. 
Moreover, in contrast to many cancers, some studies have reported an inverse relationship 
between hyperglycaemia, type-2 diabetes and meningioma risk 13-15. Such observational 
epidemiological studies can however be influenced by reverse causation, biasing findings.  
 
Mendelian randomisation (MR) uses genetic variants as instrumental variables (IVs) to assess the 
causal relationship between an exposure, such as a lifestyle-related or environmental risk factor, 
and an outcome, such as the risk of a disease 16. These genetic variants represent unconfounded 
markers of exposure, provided that these instruments are not associated with disease risk through 
an alternative mechanism 16. As these genetic variants are assigned randomly at conception, they 
are not influenced by reverse causation, and MR therefore represents an approach orthogonal to 
traditional observational epidemiological studies. If the assumptions of MR are not violated, then 
the association between the genetic instruments and the outcome of interest indicates a causal 
relationship between the exposure and outcome. Parallels have been drawn between MR and 
randomised controlled trails, in that the random assignment of variants at conception similarly 
circumvents some of the limitations of observational epidemiological studies 17.  
 
Many genetic instruments explain only a small proportion of exposure variation 18 and MR 
frameworks have therefore been developed that consider multiple genetic variants when 
estimating the causal effect of an exposure on an outcome 19. Each additional independent single 
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nucleotide polymorphisms (SNP) considered in a multi-SNP approach provides further 
information on the causal relationship, and combining all valid genetic instruments thereby 
affords a more precise estimation of the causal effect 19.  
 
To further our understanding of meningioma aetiology, we implemented a Generalised 
Summary-data-based Mendelian Randomisation (GSMR) to evaluate the causal relationship 
between 11 key obesity-related traits and meningioma risk 20. This multi-SNP MR approach is 
typically more powerful than other summary-data-based MR approaches 19. Furthermore, GSMR 
can account for linkage disequilibrium (LD) between SNPs 20. We identified genetic instruments 
for each obesity-related trait from external genome-wide association studies (GWAS). Using 
these genetic instruments in conjunction with association statistics from a recent GWAS meta-
analysis of meningioma 21,22, we estimate the causal effect of each trait on meningioma risk. 
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RESULTS  
  
We considered 11 obesity-related traits: BMI, basal metabolic rate (BMR), body fat percentage, 
diastolic blood pressure (DBP), fasting glucose, low-density lipoprotein cholesterol (LDL), high-
density lipoprotein cholesterol (HDL), systolic blood pressure (SBP), total cholesterol, 
triglycerides and waist circumference. SNPs were excluded if there were data missing in either 
the two meningioma GWAS, or the data sets used to compute LD correlations (see 
Supplementary Table S1 online). We performed Heterogeneity in Dependent Instruments 
(HEIDI) outlier analysis20 to identify those genetic instruments violating MR pleiotropy 
assumptions, identifying three BMI, three BMR, two body fat percentage and two waist 
circumference SNPs, which were further excluded from the analyses (see Supplementary Table 
S1 online). 
 
The number of SNPs used as IVs for each obesity-related trait, the proportion of variance 
explained (PVE) by these SNPs, and the mean and standard deviation (SD) for each obesity-
related trait in the original discovery study are detailed in Table 1. The PVE was calculated using 
sample size estimates from each GWAS as well as effect sizes and standard errors for each SNP 
effect estimate. The SNPs used as IVs for each obesity-related trait, along with the association 
statistics for these SNPs in respect to disease risk are shown in Supplementary Table S2 online.  
One SNP reported in the original LDL discovery study (rs9411489) has been merged with 
another SNP (rs635634), and we therefore derived meningioma association statistics using 
rs635634. 
 
The association of each IV with the respective obesity-related trait and meningioma risk, and the 
log odds ratios (ORs) estimated by GSMR, are shown in Fig. 1. At a significance threshold of 
P<0.05, risk of meningioma was not associated with BMR (ORSD=1.04, 95% confidence interval 
[CI]=0.87-1.24, P=0.67), DBP (ORSD=1.07, 95% CI=0.77-1.48, P=0.68), fasting glucose 
(ORSD=1.03, 95% CI=0.74-1.43, P=0.85), HDL (ORSD=1.03, 95% CI=0.81-1.33, P=0.79), LDL 
(ORSD=1.00, 95% CI=0.68-1.49, P=0.98), SBP (ORSD=1.02, 95% CI=0.75-1.39, P=0.89), total 
cholesterol (ORSD=1.36, 95% CI=0.79-2.34, P=0.26), triglycerides (ORSD=0.84, 95% CI=0.54-
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1.30, P=0.44) or waist circumference (ORSD=1.16, 95% CI=0.89-1.50, P=0.27) (Table 2). There 
was however support for a positive relationship between both BMI (ORSD=1.27, 95% CI=1.03-
1.56, P=0.028) and body fat percentage (ORSD=1.28, 95% CI=1.01-1.63, P=0.042) with 
meningioma risk, albeit non-significant after correction for multiple testing.  
 
We used MR-Egger regression to assess whether directional pleiotropy could affect the causal 
estimates (see Supplementary Fig. S1 and Supplementary Table S3 online). In none of these 
analyses was the intercept of the causal effect significantly different from zero (i.e. P<0.05), 
thereby providing no evidence that overall unbalanced pleiotropy biased results. 
 
No obesity-related traits were identified by the MR-Egger as being associated with meningioma 
risk (see Supplementary Table S3 online). However, whilst a positive relationship between BMI 
and risk of meningioma was estimated by GSMR (ORSD=1.27, 95% CI=1.03-1.56, P=0.028), a 
non-significant negative relationship was estimated by MR-Egger regression (ORSD=0.93, 95% 
CI=0.51-1.71, P=0.83). As MR-Egger regression can be strongly influenced by a single outlying 
variant23, we conducted leave-one-out analysis to determine whether such a variant could explain 
this disparity (see Supplementary Table S4 online). When rs663129 was removed, the OR for 
BMI and risk of meningioma estimated by MR-Egger regression was 1.06 (95% CI=0.57-2.00, 
P=0.85). Conversely, the removal of rs663129 had little effect on the OR for BMI and risk of 
meningioma estimated by GSMR (OR=1.29, 95% CI=1.05-1.60, P=0.017). This outlying variant 
therefore partly explains the difference in causal effects estimated by the two approaches. Single-
SNP analyses of each obesity-related trait did not identify any other outlying SNPs (see 
Supplementary Fig. S2 online). 
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DISCUSSION 
 
Twin and family studies have provided strong evidence for large genetic influences on obesity-
related traits, with heritability estimates for BMI of between 50% and 90%, leaving the 
remaining variance attributable to environmental influences 24. In our analysis, genetic markers 
correlated with 11 obesity-related traits were used as proxies for these traits.  
 
As for the common cancers, there is increasing evidence that obesity increases the risk of 
developing rarer tumours, such as multiple myeloma 4,25, inviting speculation that obesity and its 
related traits provide an environment supportive to tumorigenesis in general. As previously 
stated, observational epidemiological studies have provided mixed evidence on whether obesity 
influences the risk of meningioma development 5-11. Diabetes and fasting serum glucose levels 
have been identified as being inversely related to meningioma risk in some studies 8,13,14. Anti-
diabetic treatment has however paradoxically been reported as being positively related to 
meningioma risk in one study 15. Suggested mechanisms for the association of obesity and 
obesity-related traits with meningioma risk include chronic inflammation, and increased 
adipokine-mediated signalling, insulin signalling and insulin-like growth factor (IGF) signalling 
26,27. Obesity is associated with higher circulating levels of IGF-1, which is known to suppress 
apoptosis and stimulate tumour growth 28. Higher expression of components of the IGF 
signalling system have also been observed in meningioma, suggesting a role for these proteins in 
the development of these tumours 29. Furthermore, the transcription regulatory factors leptin and 
leptin receptor have been shown to be important in the proliferation and survival of patient-
derived meningioma cell lines 30. Leptin hormone concentrations are higher in individuals with 
high BMI, providing an alternative or complementary mechanism for the association of obesity 
with meningioma risk 30. Although the long-term metabolic consequences of obesity-related 
traits are highly complex, these mechanisms are compatible with the generic effect of obesity on 
cancer risk.  
 
Oestrogen pathways also provide a biological explanation for the relationship between obesity 
and some cancers, including breast and endometrial 31. Oestrogen interacts with IGF in the brain 
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32 and such hormonal factors may account for the two-fold increase in meningioma risk observed 
in women when compared to men 33. Both hormone replacement therapy 34-37 and oral 
contraceptive use 35-37 have however been inconsistently associated with meningioma risk. In 
breast cancer, a higher lifetime exposure to oestrogen, as measured using age at menarche and 
menopause, is associated with increased disease risk 38. Reported associations between lifetime 
oestrogen exposure and meningioma risk have however not been consistent 3,39, suggesting a 
complex relationship between hormone exposure, obesity and risk of meningioma.   
 
Our MR analysis provides evidence for a causal relationship between obesity, specifically higher 
BMI and body fat percentage, and meningioma risk. An advantage of using MR to identify 
causal relationships between environmental factors and disease risk is that the random allocation 
of genetic variants at conception avoids reverse causation, which may have biased causal 
estimates in previous observational epidemiological studies. MR-Egger analysis of each obesity-
related trait did not identify bias caused by directional pleiotropy (see Supplementary Table S3 
online). Therefore, whilst we cannot exclude the possibility that confounders such as type-2 
diabetes medication use may be having some effect on the causal estimates, it is unlikely that 
they are a substantial source of bias. Some potential weak instrument bias is quantified by the 
low (<10) first-stage F-statistics for BMI, BMR, body fat percentage, DBP, SBP, total 
cholesterol and waist circumference, with F-statistics of 0.9, 2.0, 1.6, 1.7, 1.6, 4.6 and 1.6 
respectively. However, F-statistics for fasting glucose, LDL, HDL and triglycerides indicates 
that these are strong IVs, with respective values of 13.0, 13.7, 12.3, 11.2, and are hence less 
likely to be affected by weak instrument bias 40.  
 
Our study does however have limited power to detect causal effects for some of the obesity-
related traits (Table 3). In particular, our study had less than 80% power to identify ORs of 0.67 
or 1.50 for DBP, fasting glucose and total cholesterol. Thus, interpretation of the null results 
found for these traits in this study are limited, as modest associations between these traits and 
meningioma risk cannot be excluded. 
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In conclusion, our analysis provides further evidence that higher BMI and body fat percentage 
are risk factors for meningioma.  
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METHODS  
 
All data used in this study were retrieved from publicly available summary statistics of published 
GWAS and we therefore did not seek ethical approval for this specific project. This study used 
no individual-level data.   
 
Genetic instruments for obesity-related traits 
We identified genetic instruments for each obesity-related trait suitable for use in MR analyses 
by considering the largest GWAS or meta-analysis of each trait conducted to date. Only 
continuous obesity-related traits were considered, as MR analysis of a binary exposure with a 
binary outcome using summary data in a two-sample setting can result in inflated causal 
estimates 41. We identified a panel of SNPs associated with each trait at a genome-wide level of 
significance (P<5×10-8) and minor allele frequency >0.01. Only studies of individuals of 
European ancestry were considered. Genetic instruments for fasting glucose were retrieved from 
an analysis by the Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC) 42, 
instruments for BMI from the Genetic Investigation of Anthropometric Traits (GIANT) 
consortium 43, instruments for HDL, LDL, total cholesterol and triglycerides from the Global 
Lipids Genetic Consortium (GLGC) 44, and instruments for BMR, body fat percentage, DBP, 
SBP and waist circumference were obtained from GWAS using data from UK Biobank 45-47. For 
each SNP used as a genetic instrument, we obtained the estimated per-allele effect on the 
obesity-related trait, the standard error of this estimate, and the chromosomal position of the SNP 
(see Supplementary Table S2 online). In order to mitigate against co-linearity between SNPs, 
which can bias causal estimates, we used MR-Base to exclude correlated SNPs at a threshold of 
r2 >0.01, retaining the SNPs with the strongest effect on the respective obesity-related trait 46,48. 
Effect size estimates and the standard errors of these estimates were standardized to represent the 
per-allele effect of the SNP on the exposure in standard deviation units 20. 
 
Meningioma association statistics  
We examined the association of the respective genetic instruments for each obesity-related trait 
with risk of meningioma using data from a recent meta-analysis of meningioma GWAS. This 
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GWAS meta-analysis includes 1,606 meningioma patients and 9,823 controls of European 
descent from two independent GWAS datasets (see Supplementary Table S5 online) 22, and after 
imputation comprises >9 million genetic variants. Details of the two independent GWAS 
datasets, including participant recruitment and the quality control procedures conducted, have 
been reported previously 22. We used MR-Base to ensure that the effect of each SNP on the 
obesity-related trait and meningioma risk corresponded to the same allele 46.  
 
Evaluating causal relationships using Mendelian randomisation  
For each obesity-related trait, we used GSMR to estimate the OR of meningioma per unit of SD 
increment of each considered risk factor 20. The GSMR R-package contains an implementation 
of the HEIDI outlier test, which can be used to identify loci that influence multiple phenotypes 
(i.e. the exposure and outcome considered in an MR analysis) 20. LD correlations between SNPs 
were estimated using data from the 1000 Genomes Project 49 and the UK10K 50. We used HEIDI 
outlier tests to identify and exclude SNPs that may have pleiotropic effects on each obesity-
related trait and meningioma risk (see Supplementary Table S1 online).  
 
To derive conclusions concerning which obesity-related traits were causally related to 
meningioma risk, we considered P<0.05 as a global significance level. To correct for multiple 
testing we applied Bonferroni-correction imposing a significance threshold of 0.0045 (i.e. 
0.05/11 traits). The power of any MR analysis depends on the PVE captured by the SNPs used as 
IVs and we therefore estimated the power of each analysis using the method from Burgess et al 
51. All statistical analyses were conducted using R (v3.1.2).  
 
We used MR-Egger regression to further assess the violation of MR assumptions caused by 
directional pleiotropy (see Supplementary Fig. S1 and Supplementary Table S3 online) 52. 
Significant difference between the slope estimated by MR-Egger regression and the intercept 
was considered evidence of violation. SNPs failing the HEIDI outlier tests were not included in 
the MR-Egger regression analyses. Furthermore, we conducted single-SNP MR-Egger analyses 
and display the results in funnel plots to allow the visual identification of any outlying SNPs (see 
Supplementary Fig. S2 online) 52. We used leave-one-out analysis, as per Burgess and 
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Thompson23, to assess whether outlying variants could be influencing causal estimates from MR-
Egger regression.  
 
Data availability 
Summary statistics for the obesity-related trait GWAS using UK Biobank data are available from 
http://www.nealelab.is/uk-biobank/. Genotype data from The Resource for Genetic 
Epidemiology Research on Aging can be downloaded from The Database of Genotypes and 
Phenotypes (dbGaP) (accession code phs000674.v2.p2). The 1000 Genomes Project and UK10K 
imputation panel data are available from the European Genome-phenome Archive (EGA, 
accession EGAD00001000776). Remaining data are available upon request. 
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Figure 1: Effects of genetic instruments on obesity-related traits and meningioma risk. 
Shown are the results for (a) BMI, (b) BMR, (c) body fat percentage, (d) DBP, (e) fasting 
glucose, (f) HDL, (g) LDL, (h) SBP, (i) total cholesterol, (j) triglycerides and (k) waist 
circumference. For each SNP, the effect for the obesity-related trait is plotted against the effect 
for meningioma risk. Dashed lines represent GSMR estimates. Error bars represent one standard 
deviation. BMI: body mass index; BMR; basal metabolic rate; DBP: diastolic blood pressure; 
GSMR: Generalised Summary-data-based Mendelian Randomisation; HDL: high-density 
lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; SNP: single nucleotide 
polymorphism.  
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Table 1: Genetic instruments used to evaluate the causal relationship between obesity-
related traits and meningioma risk.  
 
Obesity-related trait  SNPs* PVE (%) Units Source 
BMI 927 7.5 kg/m2 Yengo et al. (2018) 
BMR 677 11.2 kilojoules UK Biobank 
Body fat percentage 434 5.8 % UK Biobank 
DBP 216 3.1 mmHg UK Biobank 
Fasting glucose 27 3.0 mmol/l Scott et al. (2012) 
HDL 50 5.1 mg/dl Willer et al. (2013) 
LDL 19 2.2 mg/dl Willer et al. (2013) 
SBP 250 3.5 mmHg UK Biobank 
Total cholesterol 29 1.1 mg/dl Willer et al. (2013) 
Triglycerides 19 1.9 mg/dl Willer et al. (2013) 
Waist circumference 367 4.9 cm UK Biobank 
 
* After removal of SNPs during quality control and LD trimming.  
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Table 2: GSMR results for each obesity-related trait and meningioma risk.  
 
Obesity-related trait OR (95% CI) P-value 
BMI 1.27 (1.03-1.56) 0.028 
BMR 1.04 (0.87-1.24) 0.674 
Body fat percentage 1.28 (1.01-1.63) 0.042 
DBP 1.07 (0.77-1.48) 0.679 
Fasting glucose 1.03 (0.74-1.43) 0.853 
HDL 1.03 (0.81-1.33) 0.792 
LDL 1.00 (0.68-1.49) 0.980 
SBP 1.02 (0.75-1.39) 0.887 
Total cholesterol 1.36 (0.79-2.34) 0.264 
Triglycerides 0.84 (0.54-1.30) 0.436 
Waist circumference 1.16 (0.89-1.50) 0.267 
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Table 3: Odds ratios required for 80% study power. 
 
Obesity-related trait OR low OR high 
BMI 0.76 1.32 
BMR 0.80 1.25 
Body fat percentage 0.73 1.37 
DBP 0.65 1.53 
Fasting glucose 0.65 1.54 
HDL 0.78 1.28 
LDL 0.70 1.43 
SBP 0.67 1.49 
Total cholesterol 0.62 1.61 
Triglycerides 0.69 1.45 
Waist circumference 0.71 1.40 
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Supplementary	 Figure	 S1:	 Sca3er	 plots	 of	 gene7c	 associa7ons	 with	 the	 obesity-related	 traits	
against	gene7c	associa7ons	with	meningioma	risk.	Shown	are	the	results	for	(A)	BMI,	(B)	BMR,	(C)	
body	 fat	percentage,	 (D)	DBP,	 (E)	 fasAng	glucose,	 (F)	HDL,	 (G)	LDL,	 (H)	SBP,	 (I)	 total	 cholesterol,	 (J)	
triglycerides	and	(K)	waist	circumference.	Blue	line	represents	MR-Egger	esAmate.		
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Supplementary	Figure	S2:	Funnel	plots	 showing	 for	each	SNP	the	causal	es7mate	of	 the	obesity-
related	trait	on	meningioma,	and	the	strength	of	the	instrument.	Shown	are	the	results	for	(A)	BMI,	
(B)	 BMR,	 (C)	 body	 fat	 percentage,	 (D)	 DBP,	 (E)	 fasAng	 glucose,	 (F)	 HDL,	 (G)	 LDL,	 (H)	 SBP,	 (I)	 total	
cholesterol,	 (J)	 triglycerides	and	 (K)	waist	circumference.	Blue	 line	 represents	causal	esAmate	 from	
MR-Egger	analysis	when	all	SNPs	in	plot	are	considered.		
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